CH Barrios

Abstract GS1-04: IMpassion130: Efficacy in immune biomarker subgroups from the global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab + <i>nab</i>-paclitaxel in patients with treatment-naïve, locally advanced or metastatic triple-negative breast cancer

LA Emens, Sherene Loi, HS Rugo et al. · Cancer Research · 2019 · 81 citations

Breast Oncology, A-nabpx Efficacy, Immunology +16

P1-17-01: Figitumumab Plus Exemestane Versus Exemestane as First-Line Treatment of Postmenopausal Hormone Receptor-Positive Advanced Breast Cancer: A Randomized, Open-Label Phase II Trial.

Patrick Neven, KL Blackwell, LY Dirix et al. · Cancer Research · 2011 · 18 citations

Breast Oncology, Medicine, Figitumumab Treatment +12

Abstract S5-02: Neratinib after trastuzumab-based adjuvant therapy in early-stage HER2+ breast cancer: 3-year analysis from a phase 3 randomized, placebo-controlled, double-blind trial (ExteNET)

Arlene Chan, Suzette Delaloge, FA Holmes et al. · Cancer Research · 2016 · 13 citations

Breast Oncology, Pharmacotherapy, Trastuzumab-based Adjuvant Therapy +16

Abstract GS2-04: Efficacy results from CIBOMA/2004-01_GEICAM/2003-11 study: A randomized phase III trial assessing adjuvant capecitabine after standard chemotherapy for patients with early triple negative breast cancer

Miguel Martín, CH Barrios, Laura Torrecillas et al. · Cancer Research · 2019 · 10 citations

Surgical Oncology, Breast Oncology, Adjuvant Capecitabine +18